drugset / Trial / NCT06902896
Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
Phase 1/2
Recruiting
43 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Non-randomizedSequentialSingle-blindTreatment
Summary
To study the safety and efficacy of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of end-stage dilated cardiomyopathy and provide a new method for the treatment of end-stage dilated cardiomyopathy.
Timeline
- Start
- 2025-04-22
- Primary completion
- 2028-06-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FAP immunosuppressive CAR-DC | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | FAP immunosuppressive CAR-DC | Cell therapy | 400000 cells/kg | Intravenous |
| Subject | FAP immunosuppressive CAR-DC | Cell therapy | 800000 cells/kg | Intravenous |